Moderna, a frontrunner in the COVID-19 vaccine development race, today entered the final phase of testing required before pursuing regulatory approval, beginning the Phase III trial for their vaccine candidate mRNA-1273. The trial, titled COVE (Coronavirus Efficacy), will measure how well a 100 microgram dose of the vaccine can protect people against developing symptomatic COVID-19 […] Continue reading ->
A notorious hacking group with ties to Russia’s intelligence network has been targeting COVID-19 vaccine developers, according to the United States, United Kingdom, and Canadian government. APT29, also known as ‘The Dukes’ or ‘Cozy Bear,’ has been organizing cyber attacks in an effort to steal confidential information regarding COVID-19 vaccine development and research, according to […] Continue reading ->
Some 75 new countries have submitted expressions of interest to join the COVAX Facility, potentially supporting 90 other countries who have already joined the COVAX Advanced Market Commitment initiative created to pool demand and secure lower prices for bulk purchases of a COVID-19 vaccine. Meanwhile, Moderna is pulling ahead in the COVID-19 vaccine rat race […] Continue reading ->
Ibadan, Nigeria – The World Health Organisation (WHO) is advocating for equitable access to effective COVID-19 vaccines but developments surrounding the race to a vaccine suggest this may be extremely difficult. And health policy leaders in Africa and other low and middle-income countries are increasingly worried about their prospects for being pushed to the back […] Continue reading ->
A new Antimicrobial Resistance (AMR) Action Fund will inject nearly US $1 billion into the collapsing antibiotic development pipeline, aiming to bring two to four new antibiotics to patients by 2030. The investment, organized by the International Federation of Pharmaceutical Manufacturers & Associations and 23 different pharma companies, is the biggest single investment in antibiotic […] Continue reading ->
The United States has secured almost all of Gilead Sciences’ projected production of remdesivir – an antiviral that was shown to reduce hospitalization times for COVID-19 patients- for the next three months. US Health and Human Services (HHS) has secured 100 percent of Gilead’s projected production for July (94,200 treatment courses), 90 percent of production […] Continue reading ->